Dopaminergic regulation of postnatal development of dynorphin neurons in rat striatum

Neuropeptides

Volumn 30, Issue 1, 1996, Pages 103-107

  Sivam, S P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE NORTHWEST   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN A; OPIATE PEPTIDE; OXIDOPAMINE;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

EID: 0029912477     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(96)90062-1     Document Type: Article

References (25)

1. Civelli O, Douglass J, Goldstein A, Herbert E. Sequence and expression of the rat prodynorphin gene. Proc Natl Acad Sci 1985; 82: 4291-4295.
2. Kakidani H, Furutani Y, Takahashi H et al. Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin or dynorphin precursor. Nature 1982; 298: 245-249.
3. Weber E, Evans C J, Barchas J D. Predominance of the aminoterminal octapeptide fragment of dynorphin in rat brain regions. Nature 1982; 299: 77-79.
4. Clemens J A, Phebus L A. Dopamine depletion protects striatal neurons from ischemia-induced cell death. Life Sci 1988; 42: 707-713.
5. Gustafson E L, Moore R Y. Noradrenaline neuron plasticity in developing rat brain: effects of neonatal 6-hydroxydopamine demonstrated by dopamine-beta-hydroxylase immunocytochemistry. Dev Brain Res 1987; 37: 143-155.
6. Pifl C, Hornykiewicz O. Postsynaptic dopamine agonist properties of BHT 920 as revealed by concomitant D1 receptor stimulation. Eur J Pharmacol 1988; 146: 189-191.
7. Thompson L A, Matsumoto R R, Hohmann A G, Walker J M. Striatonigral prodynorphin: a model system for understanding opioid peptide function. Ann N Y Acad Sci 1990; 579: 192-203.
8. Vincent S, Hokfelt T, Christensson I, Terenius L. Immunohistochemical evidence for a dynorphin immunoreactivity striatonigral pathway. Eur J Pharmacol 1985; 85: 251-252.
9. Zamir N, Palkovits M, Weber E, Mezey E, Brownstein MJ. A dynorphinergic pathway of Leu-enkephalin production in rat substantia nigra. Nature 1984; 307: 643-645.
10. Sivam S P. Dopamine-dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brains. Neuropeptides 1991; 18: 201-207.
11. Sivam S P, Krause J E. The adaptation of enkephalin, tachykinin and monoamine neurons of the basal ganglia following neonatal dopaminergic denervation is dependent on the extent of dopamine depletion. Brain Res 1990; 536: 169-175.
12. Hornykiewicz O, Kish S J. Advances in neurology. In: Yahr M D, Bergmann K J, eds. Biochemical pathology of Parkinson's disease. New York: Raven Press, 1986: 19.
13. McDowell J, Kitchen I. Development of opioid systems: peptides, receptors and pharmacology. Brain Res Rev 1987; 12: 397-421.
14. Alvarez-Bolado G, Fairén A, Douglass J, Naranjo J R. Expression of the prodynorphin gene in the developing and adult cerebral cortex of the rat: an in situ hybridization study. J Comp Neurol 1990; 300: 287-300.
15. Sei C A, Dores R M. Changes in the processing of prodynorphin end products in the substantia nigra during neonatal development. Peptides 1990; 11: 89-94.
16. Breese G R, Traylor T D. Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine. Br J Pharmacol 1972; 44: 210-222.
17. Glowinski J, Iversen L L. Regional studies of catecholamines in the rat brain -1. The disposition of [3H]norepinephrine, [3H] dopamine and [3H]dopa in various regions of the brain. J Neurochem 1966; 13: 655-669.
18. Lowry O H, Rosebrough N J, Farr A L, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-274.
19. Kilts C D, Breese G R, Mailman R B. Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reverse phase HPLC with electrochemical detection. J Chromatogr 1981; 225: 347-357
20. Sivam S P. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. J Pharmacol Exp Ther 1989; 250: 818-824.
21. Winer B J. Statistical principles in experimental design. New York: McGraw-Hill, 1983.
22. Laurent-Huck F M, Anguelova E, Rene F, Stoeckel M E, Felix J M. Ontogeny of prodynorphin gene expression in the rat hypothalamus. Brain Res 1993 75: 45-53.
23. Xu M, Moratalla R, Gold L H et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 1994; 79: 729-742.
24. Li S J, Jiang H K, Stachowiak M S et al. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Mol Brain Res 1990; 8: 219-225.
25. 5-enkephalin production from either proenkephalin A or prodynorphin in human brain. Brain Res 1985; 341: 390-392.